Evidence map›Paper›PMID 42319881›Full record

ArticleACS synthetic biology2026

Tardigrade-Derived Strategy for Low-Cost Storage of Cell-Free Expression Lysates.

Marten Meckelburg, Imre Banlaki, Aukse Gaizauskaite, Henrike Niederholtmeyer

Abstract read
In one paragraph

Article in ACS synthetic biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marten MeckelburgTechnical University of Munich, Campus Straubing for Biotechnology and Sustainability, Straubing 94315, Germany.
Imre BanlakiTechnical University of Munich, Campus Straubing for Biotechnology and Sustainability, Straubing 94315, Germany.ORCID 0009-0002-8192-846X
Aukse GaizauskaiteTechnical University of Munich, Campus Straubing for Biotechnology and Sustainability, Straubing 94315, Germany.ORCID 0009-0000-1709-6932
Henrike NiederholtmeyerTechnical University of Munich, Campus Straubing for Biotechnology and Sustainability, Straubing 94315, Germany.ORCID 0000-0002-1375-0287

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-free expression systems (CFESs) are increasingly used alongside conventional biotechnological approaches to accelerate early-stage prototyping and are particularly valuable in point-of-use settings. However, their broader adoption remains limited by time- and cost-intensive preparation as well as stringent cryogenic storage requirements. To address this, several studies have explored lyophilization with protective additives to generate stable, solid-state CFES. These approaches had to balance the protection gained with a loss of activity because of the additives. In this study, we present a CFES that contains a tardigrade-derived cytosolic-abundant heat-soluble (CAHS) protein to protect the biosynthetic machinery in lysates from damage during drying. We show that the CAHS protein, without any other additives, preserves protein synthesis activity following low-cost room-temperature desiccation, while unprotected lysates are affected in mRNA synthesis kinetics and translation yields. The diversity of tardigrade-derived protective proteins is a treasure trove for cell-free synthetic biology, in particular, for making CFESs more accessible and portable.

Indexed as

TardigradaCell-Free SystemDesiccationFreeze DryingProtein BiosynthesisRNA, MessengerSynthetic BiologyRNA, MessengerCAHS proteinscell-free expressiondesiccation tolerancelow-cost lysate storagesolid-state cell lysatestardigrade

Identifiers

PMID42319881
PMCPMC13386639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.